中国处方药2024,Vol.22Issue(2) :168-170.

干眼症的药物治疗策略及研究进展

Drug treatment strategy and research progress of dry eye disease

秦红倩 许卉
中国处方药2024,Vol.22Issue(2) :168-170.

干眼症的药物治疗策略及研究进展

Drug treatment strategy and research progress of dry eye disease

秦红倩 1许卉1
扫码查看

作者信息

  • 1. 烟台大学,山东烟台 264000
  • 折叠

摘要

干眼症(DED)是一种复杂的多因素疾病,表现出不同的症状,这些症状可影响视觉功能,导致日常生活活动受限,工作效率降低,从而严重影响生活质量.本综述对目前临床上DED的治疗药物以及市场上正在开发的DED治疗策略进行总结,旨在对临床研究提供参考.

Abstract

Dry eye disease(DED)is a complex and multifactorial disease with different symptoms.These symptoms can affect visual function,resulting in limited activities of daily living and reduced work efficiency,thus seriously affecting the quality of life.This review provides a summary of the current clinical therapeutic drugs for DED and the developing therapeutic strategies for DED in the market,aiming to provide a reference for clinical research.

关键词

干眼症/治疗策略/人工泪液/非甾体抗炎药/Tivanisiran/IL-1R拮抗剂/EBI-005

Key words

Dry eye disease/Treatment options/Rrtificial tears/Nonsteroidal anti-inflammatory drugs/Tivanisiran/IL-1R antagonist/EBI-005

引用本文复制引用

出版年

2024
中国处方药
南方医药经济研究所

中国处方药

影响因子:0.649
ISSN:1671-945X
参考文献量21
段落导航相关论文